LAUSR

The use of continuous subcutaneous insulin infusion (CSII) via insulin pumps is today considered standard of care for type 1 diabetes (T1D). Closed‐loop systems combining continuous glucose monitoring with automated algorithm‐driven insulin delivery have been shown to be safe and efficacious in randomized controlled trials and real‐life studies in both paediatric and adult participants with T1D. Implementation of hybrid closed‐loop (HCL) systems has shown incremental effectiveness, with further reduction of hypoglycaemia and hyperglycaemia. Although less extensively studied in type 2 diabetes (T2D), insulin pumps have demonstrated their effectiveness in glucose control, along with a reduction in need for insulin and a neutral effect on weight. Recent studies have also shown promising results with the use of HCL systems in T2D. Cost‐effectiveness studies in both T1D and T2D have shown that pump use is cost‐effective in several countries, leading to improvements in quality‐adjusted life‐years. Insulin pumps are currently reimbursed for T1D in many European countries, but in only a few for individuals with T2D. HCL systems are to be evaluated in future trials performed in T2D to compare their incremental efficacy and cost‐effectiveness in comparison with available intensification tools which include multiple daily insulin injections, metformin, sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists. There is a need for updated guidelines for the use of CSII and HCL in individuals living with T2D based on the emerging evidence, with identification of and recommendations for the people who would benefit the most, which would eventually form a basis for reimbursement and health policies.